Irinotecan Hydrochloride|cas 100286-90-6|DC Chemicals

Cas No.:	100286-90-6
Chemical Name:	Irinotecan hydrochloride
Synonyms:	Irinotecan HCL;Irinotecan, Hydrochloride, Trihydrate;Irinotecan Hydrochloride;(S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride;(S)-4,11-DIETHYL-3,4,12,14-TETRAHYDRO-4-HYDROXY-3,14-DIOXO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL ESTER;TOPOTECIN HYDROCHLORIDE;CPT 11;Irinotecan;Irinotecan (hydrochloride);Irinotecan HCL Trihydrate;IRINOTECAN HCL(P);IRINOTECAN MONOHYDROCHLORIDE TRIHYDRATE;Campto;Campto hydrochloride;Camptothecin 11 hydrochloride;Camptothecin analog;CPT 11 hydrochloride;CPT-11 hydrochloride;Topotecin;Camptosar;Camptothecin 11;U 101440E;06X131E4OE;NSC616348;Irinotecan hydrochloride [USAN:JAN];DSSTox_RID_81249;DSSTox_CID_25953;DSSTox_GSID_45953;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hydrochloride;Irinotecan hy...
SMILES:	Cl.CCC1C2=C(N=C3C=1C=C(C=C3)OC(=O)N4CCC(CC4)N5CCCCC5)C6N(C2)C(=O)C7=C(C=6)[C@](CC)(O)C(=O)OC7
Formula:	C₃₃H₃₉ClN₄O₆
M.Wt:	623.1390
Purity:	99%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Irinotecan hydrochloride is a water soluble topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer.
Target:	Topoisomerase I
In Vivo:	Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3].
In Vitro:	Irinotecan hydrochloride is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3].
Cell Assay:	Exponentially growing cells are seeded in 20 cm2 dishes with an optimal cell number for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells, 40 h for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug[2].
Animal Administration:	Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II[1].
References:	[1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [2]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. [3]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5.

Cat. No.	Product name	Field of application
DC31079	Abarelix	Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79856	EVT0185	EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
DC79609	NCGC00685960	NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC79112	Simepdekinra	Simepdekinra (Compound 221) is a IL-17A modulator with IC50s ≤10  nM and 10-100 nM for IL-17A/A HEK-Blue and IL-17A/F HEK-Blue cells. Simepdekinra can be used for inflammatory diseases such as psoriasis, ankylosing spondylitis and psoriatic arthritis research.
DC78751	RSL3-NH2	RSL3-NH2 is a GPX4 inhibitor and Ferroptosis inducer. RSL3-NH2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
DC77831	Vicadrostat	Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813	Zeltociclib	Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77784	UNC10013	UNC10013 is a SETDB1 allosteric modulator that forms a covalent bond with Cys385 in the 3TD domain, exhibiting negative allosteric regulatory activity. It has a kinact/KI value of 1.0 × 106 M-1*s-1. UNC10013 effectively disrupts SETDB1-mediated Akt methylation and holds potential value for research in cancer and neurodegenerative diseases.
DC77740	T0080	T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE−/− mice.